Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes : A longitudinal observational study
Copyright © 2024. Published by Elsevier Masson SAS..
BACKGROUND: Cardiovascular disease is frequent in type 2 diabetes mellitus (T2DM). We investigated the relationship between skin autofluorescence (SAF) of advanced glycation end-products and later cardiovascular events (CVEs) in patients with T2DM.
RESEARCH DESIGN AND METHODS: We conducted a retrospective analysis of 504 patients hospitalized for uncontrolled and/or complicated T2DM between 2009 and 2017. SAF was measured using an AGE-Reader. Participants were followed up from admission to December 2020, for the onset of a CVE (myocardial infarction, stroke, revascularization procedures or cardiovascular death). The relationship between SAF and CVE was analyzed by multivariable Cox regression. Log-rank curves were used to compare CVE-free survival in patients whose SAF at admission was above versus below the whole-population median. The analysis was repeated in subjects without/with macroangiopathy (defined as myocardial infarction, stroke, peripheral revascularization) at baseline.
FINDINGS: During 54 months of follow-up, 69 (13.7%) patients had a CVE. Baseline SAF was significantly higher in patients with T2DM who later experienced a CVE (2.89 ± 0.70 arbitrary units versus 2.64 ± 0.62 in others, P = 0.002). This relationship was significant after adjusting for age, sex, conventional risk factors (diabetes duration, HbA1c, arterial hypertension, dyslipidemia, smoking, body mass index), vascular complications, C-reactive protein, and treatments for diabetes. The CVE-free survival curves differed between subjects whose SAF was above the whole-population median (log-rank: P = 0.002) and those whose SAF was above the macroangiopathy-free sub-population median (log-rank: P = 0.016).
CONCLUSION: SAF of advanced glycation end-products was related to a higher incidence of later CVE in patients with T2DM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Diabetes & metabolism - 50(2024), 2 vom: 15. März, Seite 101524 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alkhami, Fadi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diabet.2024.101524 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368366057 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368366057 | ||
| 003 | DE-627 | ||
| 005 | 20240319232640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2024.101524 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM368366057 | ||
| 035 | |a (NLM)38346471 | ||
| 035 | |a (PII)S1262-3636(24)00016-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alkhami, Fadi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes |b A longitudinal observational study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Masson SAS. | ||
| 520 | |a BACKGROUND: Cardiovascular disease is frequent in type 2 diabetes mellitus (T2DM). We investigated the relationship between skin autofluorescence (SAF) of advanced glycation end-products and later cardiovascular events (CVEs) in patients with T2DM | ||
| 520 | |a RESEARCH DESIGN AND METHODS: We conducted a retrospective analysis of 504 patients hospitalized for uncontrolled and/or complicated T2DM between 2009 and 2017. SAF was measured using an AGE-Reader. Participants were followed up from admission to December 2020, for the onset of a CVE (myocardial infarction, stroke, revascularization procedures or cardiovascular death). The relationship between SAF and CVE was analyzed by multivariable Cox regression. Log-rank curves were used to compare CVE-free survival in patients whose SAF at admission was above versus below the whole-population median. The analysis was repeated in subjects without/with macroangiopathy (defined as myocardial infarction, stroke, peripheral revascularization) at baseline | ||
| 520 | |a FINDINGS: During 54 months of follow-up, 69 (13.7%) patients had a CVE. Baseline SAF was significantly higher in patients with T2DM who later experienced a CVE (2.89 ± 0.70 arbitrary units versus 2.64 ± 0.62 in others, P = 0.002). This relationship was significant after adjusting for age, sex, conventional risk factors (diabetes duration, HbA1c, arterial hypertension, dyslipidemia, smoking, body mass index), vascular complications, C-reactive protein, and treatments for diabetes. The CVE-free survival curves differed between subjects whose SAF was above the whole-population median (log-rank: P = 0.002) and those whose SAF was above the macroangiopathy-free sub-population median (log-rank: P = 0.016) | ||
| 520 | |a CONCLUSION: SAF of advanced glycation end-products was related to a higher incidence of later CVE in patients with T2DM | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Advanced glycation | |
| 650 | 4 | |a Cardiovascular events | |
| 650 | 4 | |a Cardiovascular risk | |
| 650 | 4 | |a End-products | |
| 650 | 4 | |a Macroangiopathic complications | |
| 650 | 4 | |a Microangiopathic complications | |
| 650 | 4 | |a Skin autofluorescence | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a Glycation End Products, Advanced |2 NLM | |
| 700 | 1 | |a Borderie, Gauthier |e verfasserin |4 aut | |
| 700 | 1 | |a Foussard, Ninon |e verfasserin |4 aut | |
| 700 | 1 | |a Larroumet, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Barbet-Massin, Marie-Amélie |e verfasserin |4 aut | |
| 700 | 1 | |a Ferriere, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Ducos, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammedi, Kamel |e verfasserin |4 aut | |
| 700 | 1 | |a Fawaz, Sami |e verfasserin |4 aut | |
| 700 | 1 | |a Couffinhal, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Rigalleau, Vincent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolism |d 1998 |g 50(2024), 2 vom: 15. März, Seite 101524 |w (DE-627)NLM086696130 |x 1878-1780 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:101524 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabet.2024.101524 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 2 |b 15 |c 03 |h 101524 | ||